Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Variants & evidence
788 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TYK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 4 | accepted | EID12803In this 2022 study, the authors investigate the oncogenic role of the MYB::TYK2 fusion gene in high-risk B-lymphoblastic leukemia (HR B-ALL). TYK2 rearrangements are identified as recurrent events in … (full text at CIViC) PMID 35022522 · Shirazi et al., 2022 · Open in CIViC | civic |
| WEE1 Mutation1 | ||||||||
| (oncogenic) | Diffuse Large B-Cell LymphomaCURATED_BROADER | Oncogenic | E | Supports Oncogenicity | 3 | submitted | EID11995This gene was identified as recurrently mutated in an analysis of 574 DLBCL exomes. Incidence is less than 3% in most cohorts so its relevance remains unclear. PMID 29641966 · Schmitz et al., 2018 · Open in CIViC | civic |
| WEE1 Overexpression1 | ||||||||
| Adavosertib | Acute Lymphoblastic Leukemia | Predictive | D | Does Not Support Sensitivity Response | 2 | submitted | EID9231Through a preclinical trial WEE1 expression evaluated in acute lymphoblastic leukemia cell lines (ALL) shows exceptionally high expression in samples (n=58, 44 diagnosis samples and 14 unpaired relaps… (full text at CIViC) PMID 30068368 · Ghelli Luserna Di Rorà et al., 2018 · Open in CIViC | civic |
| WNK1 mutation1 | ||||||||
| (oncogenic) | Burkitt Lymphoma | Oncogenic | E | Supports Oncogenicity | 3 | submitted | EID11823Described in recent genome-wide study of BL and DLBCL PMID 36201743 · Thomas et al., 2023 · Open in CIViC | civic |
| XPO1 Mutation1 | ||||||||
| (oncogenic) | Diffuse Large B-Cell LymphomaCURATED_BROADER | Oncogenic | E | Supports Oncogenicity | 4 | submitted | EID11996The authors applied exome sequencing to 14 relapsed/refractory (R/R) DLBCLs PMID 26608593 · Mareschal et al., 2016 · Open in CIViC | civic |
| ABL2 Fusion9 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | B | Supports Positive | 2 | submitted | EID13064An adult patient (>18 years old) with B-ALL harbored an in-frame ZC3HAV1::ABL2 fusion, identified by targeted RNA sequencing, with no IKZF1 deletion, and presented with a white blood cell count of 72 … (full text at CIViC) PMID 33781217 · Norvilas et al., 2021 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | submitted | EID12962A 10-year-old female (Case #62) with B-ALL harbored a ZC3HAV1::ABL2 fusion and a PAX5 deletion. The fusion was identified by RNA sequencing and confirmed by RT-PCR and Sanger sequencing; breakpoints w… (full text at CIViC) PMID 27265895 · Lilljebjörn et al., 2016 · Open in CIViC | civic |
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Prognostic | C | Supports | ||||
| ZEB1 Expression6 | ||||||||
| (prognostic) | Mantle Cell Lymphoma | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12499In a tissue micro array from 46 cases histologically classified as MCL according to WHO criteria, 50% were positive for ZEB1 expression. ZEB1 expression correlated with beta catenin (Spearman correlat… (full text at CIViC) PMID 24013721 · Sánchez-Tilló et al., 2014 · Open in CIViC | civic |
| (oncogenic) | Mantle Cell Lymphoma | Oncogenic | D | Supports Oncogenicity | 2 | submitted | EID12501In a tissue micro array from 46 cases histologically classified as MCL according to WHO criteria, 50% were positive for ZEB1 expression. ZEB1 expression correlated with beta catenin (Spearman correlat… (full text at CIViC) PMID 24013721 · Sánchez-Tilló et al., 2014 · Open in CIViC | civic |
| Cytarabine + Doxorubicin + GemcitabineSubstitutes | Mantle Cell Lymphoma | Predictive | D | |||||
| PDGFRB e9::e91 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12480A male adolescent patient with study ID SJBALL267_D was reported by gene expression profile to have Ph-like non CRLF2 B-ALL. White blood count was 1.7. WGS and RNA-seq was performed. ZEB2::PDGFR joini… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| PDGFRB Fusion1 | ||||||||
| Dasatinib + ImatinibSubstitutes | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12481Xenograft models of 10 Ph-like ALL tumors including ZEB2-PDGFRB were generated from engrafting primary human leukemia cells into NOD-SCID IL2R gamma null mice. The authors state that the xenograft cel… (full text at CIViC) | civic |
| BZW1 Fusion + PDGFRB FusionPDGFRBBZW11 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12482A patient is reported with karyotype 46,XX,del(12)(p13)[6]/46,XX[19] to have Ph-like other ALL of B-ALL Lineage by expression profiling. Age at diagnosis was 16.674, termed Adolescent and Young Adult,… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC | civic |
| ZFP36L1 Mutation1 | ||||||||
| (oncogenic) | Diffuse Large B-Cell LymphomaCURATED_BROADER | Oncogenic | E | Supports Oncogenicity | 4 | submitted | EID11997The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations. PMID 29713087 · Chapuy et al., 2018 · Open in CIViC | civic |
| ABL1 Fusion9 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Prognostic | B | Supports Better Outcome | 4 | accepted | EID9149A multicenter, retrospective, cohort study that included 122 paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine… (full text at CIViC) PMID 33357483 · den Boer et al., 2021 · Open in CIViC | civic |
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID12638In a multicentre retrospective cohort study of 122 paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion (ABL1 fusion-positive, ABL2 fusion-positive, CSF1R fusion-positive, and P… (full text at CIViC) PMID 33357483 · den Boer et al., 2021 · Open in CIViC | civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | |||||
| FGFR1 Fusion + FGFR1 Fusion + FGFR1 Translocation + FGFR1 Fusion + FGFR1 Fusion2 | ||||||||
| Pemigatinib | Lymphoid Leukemia | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12241In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) | civic |
| 〃 | Lymphoma | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12242In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… (full text at CIViC) | civic |
| JAK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7706This study included 1389 cases of high-risk pediatric B-ALL, out of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| ZNF292 Mutation1 | ||||||||
| (oncogenic) | Diffuse Large B-Cell LymphomaCURATED_BROADER | Oncogenic | E | Supports Oncogenicity | 3 | submitted | EID12002This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC | civic |
| JAK2 Fusion1 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7999In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. The ZNF430-JAK2 fusion is rare; in this study inv… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC | civic |
Data updated 13 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| submitted |
EID13063A male patient older than 10 years with B-ALL harbored a ZC3HAV1(exon 12)::ABL2(exon 3) fusion and a concomitant IKZF1 deletion, presenting with a white blood cell count >50 × 10⁹/L. He was enrolled o… (full text at CIViC) PMID 29507076 · Tran et al., 2018 · Open in CIViC |
| civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | submitted | EID11620B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 2 patients (ages 6.4 and 10.4 yea… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| (oncogenic) | Adult B Acute Lymphoblastic LeukemiaALIAS | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12963A 16.6-year-old Taiwanese male (Case #299) with B-ALL harbored a ZC3HAV1(exon 12)::ABL2(exon 2) fusion and concurrent deletions of CDKN2A/2B, PAX5 (exons 2–5), and IKZF1 (exons 2–8). The fusion was de… (full text at CIViC) PMID 33707599 · Hsu et al., 2021 · Open in CIViC | civic |
| Asciminib + BCR-ABL Inhibitor HS-10382Substitutes | B Lymphoblastic Leukemia/Lymphoma with Intrachromosomal Amplification of Chromosome 21ALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12504ABL2-rearranged (ABL2r) acute lymphoblastic leukemia (ALL) is a high-risk subtype of Ph-like ALL, typically treated with intensive chemotherapy. The ZC3HAV1::ABL2 fusion is a rare mutation in ABL2r an… (full text at CIViC) PMID 40678005 · Lagonik et al., 2025 · Open in CIViC | civic |
| Chemotherapy + DasatinibCombination | B Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID12969A 38-year-old male with Ph-negative B ALL was found to harbor a ZC3HAV1 ABL2 rearrangement identified by massively parallel DNA sequencing (MPDS), consistent with a Philadelphia-like genotype. The leu… (full text at CIViC) PMID 28430957 · Chen et al., 2016 · Open in CIViC | civic |
| Imatinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID9804An 18-year-old male with B-ALL presented with hyperleukocytosis (WBC 171×10⁹/L, 90% blasts). Conventional cytogenetics showed a normal male karyotype (46,XY), and FISH/PCR were negative for ETV6-RUNX1… (full text at CIViC) PMID 31723830 · Decool et al., 2019 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID12513A 27-year-old male (Patient #17, Table 1) with B-ALL harbored a ZC3HAV1(exon 12)::ABL2(exon 2) fusion, concurrent CD200-BTLA and IKZF1 (exons 2–7) deletions, and a gain of chromosome X, presenting wit… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC | civic |
| Supports Resistance |
| 2 |
| accepted |
EID899Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine. PMID 24013721 · Sánchez-Tilló et al., 2014 · Open in CIViC |
| civic |
| Doxorubicin + SalinomycinCombination | Mantle Cell Lymphoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID900Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine. the combination of … (full text at CIViC) PMID 24013721 · Sánchez-Tilló et al., 2014 · Open in CIViC | civic |
| Salinomycin | Mantle Cell Lymphoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID12500In a tissue micro array from 46 cases histologically classified as MCL according to WHO criteria, 50% were positive for ZEB1 expression. ZEB1 expression correlated with beta catenin (Spearman correlat… (full text at CIViC) PMID 24013721 · Sánchez-Tilló et al., 2014 · Open in CIViC | civic |
| Vincristine | Mantle Cell Lymphoma | Predictive | D | Does Not Support Resistance | 2 | submitted | EID12502In ZEB1 positive MCL cell line Granta-519, cells were treated with control shRNA or shZEB1, and then incubated with varying concentrations of vincristine. No difference in cell viability was seen over… (full text at CIViC) PMID 24013721 · Sánchez-Tilló et al., 2014 · Open in CIViC | civic |
| Supports Positive |
| 2 |
| accepted |
EID9077This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq perf… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID9152Study comprised 574 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and focused on B-other/BCR-ABL-like which were identified by hierarchical clustering of gene e… (full text at CIViC) PMID 27894077 · Boer et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID11619B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 3 of 4 patients (ages 2.2, 2.6, a… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID12635A study of 204 children with B-cell precursor acute lymphoblastic leukemia from three Dutch trials (DCOG ALL-8, 9, 10) and two German trials (COALL 06-97, 07-03) included 73 cases of BCR-ABL1-like B-A… (full text at CIViC) | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID9151A 18-month-old female with B-cell acute lymphoblastic leukemia. Chromosome and FISH analysis using a BCR-ABL1 probe confirmed the involvement of ABL1 in a t(9;10)(q34;q22.3) translocation. Follow-up m… (full text at CIViC) PMID 18007576 · Soler et al., 2008 · Open in CIViC | civic |
| Chemotherapy + DasatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID11119An 11 year old female (46,XX) had B-ALL. The patient received a 4-drug induction and end induction day 29 MRD was 5.4%. LDA card was used to analyze the patient and the leukemia was determined to be P… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| Chemotherapy + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID12615A pediatric patient had a hematopathologic diagnosis of B-ALL determined through bone marrow aspirate analysis. The patient had a hemoglobin level of 3 g/dL, severe neutropenia, and a normal platelet … (full text at CIViC) PMID 38749501 · Booth et al., 2025 · Open in CIViC | civic |